Real-Time Detection of ESR1 Mutation in Blood by Droplet Digital PCR in the PADA-1 Trial: Feasibility and Cross-Validation with NGS

Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1

(2022) Frédérique Berger et al.   BMJ Open

A single droplet digital PCR for ESR1 activating mutations detection in plasma

(2020) Emmanuelle Jeannot et al.   ONCOGENE

Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial

(2020) Nicholas C Turner et al.   LANCET ONCOLOGY

ESR1 mutations: a new biomarker in breast cancer

(2019) Marcela Carausu et al.   EXPERT REVIEW OF MOLECULAR DIAGNOSTICS

Plasma next generation sequencing and droplet digital PCR‐based detection of epidermal growth factor receptor (EGFR) mutations in patients with advanced lung cancer treated with subsequent‐line osimertinib

(2019) Pei N. Ding et al.   Thoracic Cancer

Amplicon-based next-generation sequencing of plasma cell-free DNA for detection of driver and resistance mutations in advanced non-small cell lung cancer

(2018) N Guibert et al.   ANNALS OF ONCOLOGY

Measuring KRAS Mutations in Circulating Tumor DNA by Droplet Digital PCR and Next-Generation Sequencing

(2018) Christina Demuth et al.   Translational Oncology

Clinical Implications of ESR1 Mutations in Hormone Receptor-Positive Advanced Breast Cancer

(2017) Tomas Reinert et al.   Frontiers in Oncology

PlasmaESR1Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer

(2016) Charlotte Fribbens et al.   JOURNAL OF CLINICAL ONCOLOGY

ActivatingESR1Mutations Differentially Affect the Efficacy of ER Antagonists

(2016) Weiyi Toy et al.   Cancer Discovery

D538G Mutation in Estrogen Receptor- : A Novel Mechanism for Acquired Endocrine Resistance in Breast Cancer

(2013) K. Merenbakh-Lamin et al.   CANCER RESEARCH

ESR1 ligand-binding domain mutations in hormone-resistant breast cancer

(2013) Weiyi Toy et al.   NATURE GENETICS

Activating ESR1 mutations in hormone-resistant metastatic breast cancer

(2013) Dan R Robinson et al.   NATURE GENETICS

Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived Xenografts

(2013) Shunqiang Li et al.   Cell Reports